Literature DB >> 33181788

Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.

Debika Bhattacharya1, Rong Guo1, Chi-Hong Tseng1, Lynda Emel2, Ren Sun1, Shih-Hsin Chiu1, Lynda Stranix-Chibanda3, Tsungai Chipato3, Neaka Z Mohtashemi1, Kenneth Kintu4, Karim P Manji5, Dhayendre Moodley6, Chloe L Thio7, Yvonne Maldonado8, Judith S Currier1.   

Abstract

BACKGROUND: There is limited information on perinatal outcomes in HIV-hepatitis B virus (HBV) coinfection.
METHODS: HIV Prevention Trials Network (HPTN) 046 was a randomized double-blind placebo-controlled trial of perinatal transmission that evaluated 6 months of infant nevirapine versus placebo among breast-fed infants. Women living with HIV and their infants enrolled in sub-Saharan Africa from 2007 to 2010; 78% received antiretroviral therapy (ART). Maternal samples were tested for hepatitis B surface antigen (HBsAg). High and low HBV viral load (VL) was defined as ≥106 IU/mL and <106 IU/mL. The association between HIV-HBV coinfection and maternal and infant outcomes was assessed using multivariate (MV) logistic and Cox regression.
RESULTS: Among 2025 women, 88 (4.3%) had HBV. HIV-HBV women with high HBV VL had lower median CD4, versus HIV alone or HIV-HBV women with low HBV VL [320, 490 and 434 cells/mm3, respectively (P < 0.007)]. In MV analysis, adjusted for maternal CD4, age and maternal ART, infants born to women with high HBV VL were more likely to be low birth weight (LBW), versus HIV+/HBV- and low HBV VL women: [30% (3/10) vs. 10% (194/1953) vs. 6% (5/78), respectively, P = 0.03). High HBV VL was associated with HIV perinatal transmission [(hazard ratio 6.75 (95% confidence interval (CI): 1.86 - 24.50)]. There was no impact on infant mortality or maternal outcomes at 18 months.
CONCLUSIONS: In HIV-HBV women, high HBV viral loads increase the risk of LBW and potentially HIV perinatal transmission. Reduction of antepartum HBV viremia may have beneficial effects beyond the prevention of HBV perinatal transmission.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33181788      PMCID: PMC7855346          DOI: 10.1097/INF.0000000000002980

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   3.806


  27 in total

1.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

2.  Maternal hepatitis B virus infection and risk of preterm birth in China.

Authors:  Qi-Tao Huang; Mei Zhong
Journal:  Lancet Glob Health       Date:  2017-06       Impact factor: 26.763

3.  Maternal pre-pregnancy infection with hepatitis B virus and the risk of preterm birth: a population-based cohort study.

Authors:  Jue Liu; Shikun Zhang; Min Liu; Qiaomei Wang; Haiping Shen; Yiping Zhang
Journal:  Lancet Glob Health       Date:  2017-06       Impact factor: 26.763

4.  HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study.

Authors:  François Rouet; Marie-Laure Chaix; André Inwoley; Philippe Msellati; Ida Viho; Patrice Combe; Valériane Leroy; François Dabis; Christine Rouzioux
Journal:  J Med Virol       Date:  2004-09       Impact factor: 2.327

5.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

Authors:  Uchenna H Iloeje; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Chien-Jen Chen
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

6.  Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.

Authors:  Abubaker Bedri; Berhanu Gudetta; Abdulhamid Isehak; Solomon Kumbi; Sileshi Lulseged; Yohannes Mengistu; Arvind V Bhore; Ramesh Bhosale; Venkat Varadhrajan; Nikhil Gupte; Jayagowri Sastry; Nishi Suryavanshi; Srikanth Tripathy; Francis Mmiro; Michael Mubiru; Carolyne Onyango; Adrian Taylor; Philippa Musoke; Clemensia Nakabiito; Aida Abashawl; Rahel Adamu; Gretchen Antelman; Robert C Bollinger; Patricia Bright; Mohammad A Chaudhary; Jacqueline Coberly; Laura Guay; Mary Glenn Fowler; Amita Gupta; Elham Hassen; J Brooks Jackson; Lawrence H Moulton; Uma Nayak; Saad B Omer; Lidia Propper; Malathi Ram; Vivian Rexroad; Andrea J Ruff; Anita Shankar; Sheryl Zwerski
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

7.  Maternal hepatitis B surface antigen status and incidence of pre-eclampsia.

Authors:  T T Lao; D S Sahota; Y K Y Cheng; L W Law; T Y Leung
Journal:  J Viral Hepat       Date:  2013-05       Impact factor: 3.728

8.  Pregnancy outcomes among chronic carriers of hepatitis B virus.

Authors:  Sirinart Sirilert; Kuntharee Traisrisilp; Pannee Sirivatanapa; Theera Tongsong
Journal:  Int J Gynaecol Obstet       Date:  2014-04-24       Impact factor: 3.561

9.  Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience.

Authors:  Nafiisah Chotun; Wolfgang Preiser; Christoffel Johannes van Rensburg; Pedro Fernandez; Gerhard Barnard Theron; Dieter Glebe; Monique Ingrid Andersson
Journal:  PLoS One       Date:  2017-07-21       Impact factor: 3.240

10.  Maternal Hepatitis B Infection and Pregnancy Outcomes in the United States: A Population-Based Cohort Study.

Authors:  Kristina L Bajema; Helen C Stankiewicz Karita; Mark W Tenforde; Stephen E Hawes; Renee Heffron
Journal:  Open Forum Infect Dis       Date:  2018-06-09       Impact factor: 3.835

View more
  1 in total

1.  Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection.

Authors:  Flavia Matovu Kiweewa; Camlin Tierney; Kevin Butler; Marion G Peters; Tichaona Vhembo; Dhayendre Moodley; Vani Govender; Neaka Mohtashemi; Hannah Ship; Philippa Musoke; Dingase Dula; Kathy George; Nahida Chakhtoura; Mary G Fowler; Judith S Currier; Debika Bhattacharya
Journal:  J Acquir Immune Defic Syndr       Date:  2022-05-27       Impact factor: 3.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.